RECRUITING
I'm interested ...!!
Seaweed-derived Rhamnan Sulfate and Vascular Function
The primary aim of the proposed investigation is to examine the hypothesis that a relatively short period of rhamnan sulfate supplementation would improve key markers of vascular dysfunction in middle-aged and older adults with at least one risk factors for cardiovascular disease.
Conditions:
🦠 Cardiovascular Diseases
🗓️ Study Start (Actual) 1 April 2023
🗓️ Primary Completion (Estimated) 1 May 2024
✅ Study Completion (Estimated) 1 May 2024
👥 Enrollment (Estimated) 15
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 Austin, Texas, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * at least one risk factor for cardiovascular disease (e.g., dyslipidemia, hypertension, obesity, impaired fasting glucose)
    • * a BMI of \<40 kg/m2

    Exclusion Criteria:

    • * gastrointestinal disorders and/or renal disease
    • * pregnancy or lactation
    • * strenuous physical activity (\>3 times/week)
    • * alcohol abuse
Ages Eligible for Study: 35 Years to 85 Years (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 28 November 2022
  • First Submitted that Met QC Criteria 6 December 2022
  • First Posted 14 December 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 8 May 2023
  • Last Update Posted 10 May 2023
  • Last Verified May 2023
I'm interested ...!!